Miles Linde

Postdoctoral fellow @fredhutch co-advised by @GhajarLab and Dr. Stanley Riddell. Studying how the immune system regulates breast cancer dormancy and metastasis.

[Miles Linde @mileslinde]

I am so excited to finally see my PhD work out in @CD_AACR. We were able to investigate the immunotherapeutic benefit of reprogramming cancer cells into antigen presenting cells and were surprised by the dramatic responses we observed. A brief thread on our findings:

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Reprogramming Cancer into Antigen Presenting Cells as a Novel #Immunotherapy - by @mileslinde @majetilab and colleagues @StanfordMed https://t.co/5UvT9pemO5

[Waggoner Lab @LabWaggoner]

c-Jun overexpression fails to prevent CAR T cell exhaustion in tumors, but PD-L1 blockade restores c-Jun levels and CAR T cell activity @SciImmunology
https://t.co/BPDC5jHF6x @fredhutch

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML, but Is Associated With Increased Leukemia Stem Cell Frequency - by @ThomasKoehnke, @DKarigane
@majetilab and colleagues https://t.co/msxTdMAOvY @StanfordMed

[Miles Linde @mileslinde]

@amycfanphd @RaviMajetiMD @fredhutch @majetilab @ThomasKoehnke I can’t express how proud I am to have achieved this level of pun excellence.

[Miles Linde @mileslinde]

What a blast to see @RaviMajetiMD at @fredhutch giving the TST seminar this afternoon. Exciting recent work from close @majetilab friends @ThomasKoehnke, @amycfanphd, and Daiki on clonal competition in AML and DNMT3A’s role in leukemia initiation. Proud to be a Majeti lab alum!

[Miles Linde @mileslinde]

@amycfanphd @RaviMajetiMD @fredhutch @majetilab @ThomasKoehnke Lol. Pun absolutely not intended, but hilarious! This is why I a miss you too!

[OncoDaily @oncodaily]

Our work on ASXL1 mutations in clonal hematopoiesis and myeloid malignancies - @ThomasKoehnke
@BCD_AACR

#BloodCancer #Cancer #Leukemia #MyeloidMalignancies #OncoDaily #Oncology #TothovaLab

https://t.co/8BePoch3wl

[Thomas Köhnke @ThomasKoehnke]

Excited to share our work on ASXL1 mutations in clonal hematopoiesis and myeloid malignancies, out in Blood Cancer Discovery @BCD_AACR https://t.co/gU103pkrn1

[Cancer Discovery @CD_AACR]

Read this week's Cancer Discovery #ResearchWatch:
Relative Scarcity of Disseminated Tumor Cells Enables Immune Evasion, summarizing the work of Erica T. Goddard, @mileslinde, Stanley R. Riddell, @GhajarLab et al.
https://t.co/zPLxFaHa4K
@fredhutch

[ACIR @ACIR_org]

While dormant disseminated tumor cells (DTCs) downregulate MHC-I, the primarily evade antitumor immunity though “relative scarcity”. More details here 👉 https://t.co/hnm3aWrihk  @fredhutch  @GhajarLab

[Cancer Cell @Cancer_Cell]

Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies https://t.co/CIsOKGG5xq

[Met-X @FredHutch_Met_X]

Our @GhajarLab and Riddell Lab team up for a study that explains why dormant tumor cells evade immune surveillance, and how this can be overcome towards curative therapy.

This is what #METX aims to achieve more of.

[Cyrus Ghajar @GhajarLab]

Our latest - in joint collaboration w/ Stan Riddell’s Lab here at the Hutch – reveals a novel mode of immune evasion we call “relative scarcity” that explains why dormant disseminated tumor cells escape surveillance by antigen-directed T cells:

https://t.co/G9HoGkkwmu

(1/n)

[Miles Linde @mileslinde]

@Cancer_Cell @Montse_Rojo_PhD @JAguirreGhiso @GhajarLab https://t.co/j1fdgx64mj

[Miles Linde @mileslinde]

Disseminated tumor cells (DTCs) -the root of metastatic relapse- evade T cell immunosurveillance at least in part through infrequent interactions with antigen specific T cells. This paucity of interactions can be overcome with T cell immunotherapy. https://t.co/JF9Tw2KhqH

[Miles Linde @mileslinde]

@Cancer_Cell @Montse_Rojo_PhD @JAguirreGhiso Finally, go check out @GhajarLab’s thread for a thorough discussion on our findings (and even more thank yous to collaborators and funding)!

[Blood Cancer Discovery @BCD_AACR]

IDH1-mutant preleukemic #hematopoietic #stemcells can be eliminated by inhibition of oxidative phosphorylation, by Niklas Landberg, @majetilab et al.
https://t.co/0FsAVjYBkR
@StanfordMed #LeuSM

[Cancer Discovery @CD_AACR]

In the May issue—
Reprogramming Cancer into Antigen Presenting Cells as a Novel #Immunotherapy, by @mileslinde, @majetilab et al.
https://t.co/4s4W2lpM2W
@StanfordMed